NCT04490850 (EPI-COVID-POP) is a NA clinical trial of Blood sample in Coronavirus Infection, sponsored by Institut Pasteur.

Who is sponsoring NCT04490850?

NCT04490850 is sponsored by Institut Pasteur.

What drugs are being tested in NCT04490850?

Interventions in NCT04490850: Blood sample.

What condition does NCT04490850 study?

NCT04490850 studies Coronavirus Infection, Severe Acute Respiratory Syndrome, SARS-CoV Infection, Covid19.

Is NCT04490850 still recruiting?

NCT04490850 is currently completed. Last updated 15 February 2022.

Last reviewed 2022-02-15 · How we verify

NCT04490850: EPI-COVID-POP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Seroprevalence Study in French Guiana

Completed NA Last updated 15 February 2022

What this trial tests

NA trial testing Blood sample in Coronavirus Infection in 3,541 participants. Completed in 24 September 2021.

Timeline

15 July 2020

Primary endpoint
24 September 2021

24 September 2021

Quick facts

Lead sponsor	Institut Pasteur
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	3,541
Start date	15 July 2020
Primary completion	24 September 2021
Estimated completion	24 September 2021
Sites	5 locations across French Guiana

Drugs / interventions tested

Blood sample — full drug profile →

Conditions studied

Coronavirus Infection — all drugs for Coronavirus Infection →
Severe Acute Respiratory Syndrome — all drugs for Severe Acute Respiratory Syndrome →
SARS-CoV Infection — all drugs for SARS-CoV Infection →
Covid19 — all drugs for Covid19 →

Sponsor

Institut Pasteur — full company profile →

Who can join

Eligibility, any sex, with Coronavirus Infection or Severe Acute Respiratory Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.
Flamand C, Alves Sarmento C, Enfissi A, Bailly S, et al · · 2021 · cited 13× · PMID 34767549 · DOI 10.1371/journal.pntd.0009945
Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana
Flamand C, Enfissi A, Bailly S, Sarmento CA, et al · · 2020 · DOI 10.1101/2020.09.27.20202465

Verify or expand the search:

Other trials of Blood sample

Trials testing the same drug.

NCT07226466 — Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer · not yet recruiting
NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07030205 — Resting-state Imaging and OSteoporosiS · NA · recruiting
NCT07295808 — Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN) · NA · recruiting

Other recruiting trials for Coronavirus Infection

Currently open trials in the same condition.

NCT04885504 — Post COVID-19 Biorepository · recruiting
NCT04445454 — Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection · Phase 1, PHASE2 · recruiting
NCT04510025 — Capturing MultiORgan Effects of COVID-19 · recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting

Other Institut Pasteur trials

Trials by the same sponsor.

NCT07205913 — Gut Microbiota, Diet-INDuced Obesity and Type 2 Diabetes in New Caledonia - MIND · not yet recruiting
NCT06945822 — Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI · NA · not yet recruiting
NCT05821478 — Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients · Phase 3 · recruiting
NCT06769815 — Host Immunity, Plasmodium and Pathogens Co-Infections · NA · not yet recruiting
NCT06718127 — Description of the Immune Response to Yellow Fever Vaccination · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04490850 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Pasteur
Last refreshed: 15 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04490850.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing